|
Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL). |
|
|
Honoraria - ADC Therapeutics; Lilly |
Consulting or Advisory Role - Abbvie; ADC Therapeutics |
Research Funding - Adaptive Biotechnologies; Ipsen |
|
|
Stock and Other Ownership Interests - BeiGene |
Research Funding - BeiGene |
|
|
No Relationships to Disclose |
|
|
Employment - Real Chemistry |
|
|
Employment - Real Chemistry |
Stock and Other Ownership Interests - Real Chemistry |
|
|
|
Stock and Other Ownership Interests - BeiGene |